Clinical Trial Update: Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating consolidation treatment with ponatinib 15 mg on treatment-free remission rates in patients with chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• ponatinib 15 mg (ponatinib)

Snippet

Sponsor: Fundación Teófilo Hernando, Spain | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: UNKNOWN